Abstract:The Hippo pathway plays a critical role in organ size control in development. Deregulation of the Hippo pathway leads to drastic enlargement of organs due to increased cell proliferation, inhibition of apoptosis, and dedifferentiation of differentiated cells. Interestingly, deregulation of the Hippo pathway also plays a critical role in tumorigenesis. However, precise roles of the Hippo pathway in tumorigenesis are unclear. By generating genetically defined liver tumor-initiating cells (TICs) with Hippo pathway inactivation or YAP activation, we found that the Hippo pathway unexpectedly mediates a crosstalk between TICs and the immune system. Via cytokines induced by YAP, TICs actively recruit M2 macrophages from as early as the single-cell stage. Elimination of TIC-associated macrophages (TICAMs) abolishes tumorigenesis in a manner dependent on the immune system. Furthermore, YAP activation has been observed in TICs induced by pathologically relevant oncogenes in murine livers and in human hepatocellular carcinoma (HCC) precancerous lesions. These results demonstrate for the first time that macrophages play a decisive role in the survival of single TIC in vivo and provide a proof of principle for TIC elimination by targeting YAP or M2 macrophages. Furthermore, we found that YAP induces leukocyte-specific integrin β2 (ITGB2) expression in cancer cells, thereby promoting cell invasion through the endothelium in a manner mimicking leukocytes. Through independent biochemical purification and a functional screen, we further identified PR/SET domain 4 (PRDM4) as a transcription factor interacting with the WW domains of YAP to mediate ITGB2 expression and cell invasion. Consistently, ITGB2 and PRDM4 mRNA levels are significantly increased in metastatic prostate cancer. In addition, PRDM4 contributes to YAP-induced tumorigenesis, possibly via mediating the expression of other YAP target genes. Our results demonstrate that YAP promotes cell invasion by inducing leukocyte-specific integrin expression and identify PRDM4 as a novel transcription factor for YAP targets. Citation Format: Xiaocan Guo, Huan Liu, Xiaolei Cao, Bin Zhao. The Hippo pathway in cancer [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr IA21.

The posttranslational modifications of Hippo-YAP pathway in cancer

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

YAP/TAZ for Cancer Therapy: Opportunities and Challenges (Review).

The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: an Updated Version.

The Hippo-YAP pathway: new connections between regulation of organ size and cancer.

New Insights into Posttranslational Modifications of Hippo Pathway in Carcinogenesis and Therapeutics.

Targeting the Hippo Pathway for Anti-cancer Therapies.

Hippo-Yap Signaling Pathway: A New Paradigm for Cancer Therapy

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers

Abstract IA21: the Hippo Pathway in Cancer

Molecular mechanisms of the mammalian Hippo signaling pathway.

TEAD Mediates YAP-dependent Gene Induction and Growth Control

Yap and Taz Take Center Stage in Cancer

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

Angiomotin is a Novel Hippo Pathway Component That Inhibits YAP Oncoprotein.

New insights into the ambivalent role of YAP/TAZ in human cancers

Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ

Integration of Mechanical and Chemical Signals by YAP and TAZ Transcription Coactivators.

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

Context-dependent transcriptional regulations of YAP/TAZ in cancer